Qiagen is back in focus after reports that several private equity firms, including EQT, Advent and KKR, are exploring a potential takeover at about $50 per share. The takeover speculation comes after a weaker year to date for Qiagen, with the share price down 12.74% on a year to date basis, though a 12.13% one-month return and a recent spike of over 10% suggest short-term momentum has picked up. Qiagen last closed at $41.51, while the most followed narrative sets fair value at $43.96, framing the takeover talk against an already supportive valuation backdrop. However, the current price-to-earnings ratio of 21.3 times is higher than the modelled fair ratio of 19.9 times, suggesting some valuation risk even though the stock trades on a lower multiple than peers and the wider Global Life Sciences industry.
Qiagen NVTakeover speculation at $50 per share, above current price of $41.51, is positive for Qiagen shareholders.
EQT Corporation
KKR & Co. Inc.